Valneva (VALN) has granted an exclusive global license to Elaris FlexCo for antigen technology targeting Clostridioides difficile bacterium, Elaris said Wednesday.
Under the deal, Elaris said it will use the technology along with additional proprietary components to develop a vaccine that will broaden protection against C. difficile infection. Clinical studies are expected to start around 2027, the company added.
The agreement includes regulatory and commercial milestone payments and royalties on future sales, Elaris said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments